Pilot Imaging Study of Leukemia
Key facts
- Where
- Atlanta, Oklahoma City, and Washington D.C., United StatesSee the 3 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 4 to 80 with high-risk acute leukemia or myeloma that came back or did not respond to treatment. They will have 18F FLT imaging without sedation.
- Age
- 4 to 80 years
- Sex
- All sexes can join.
- Disease stage
- High-risk relapsed or refractory acute lymphocytic leukemia, acute myeloid leukemia, ambiguous lineage leukemia or myeloma.
- Earlier treatment
- Anticipated immunotherapy, or other non-immune treatment such as chemotherapy or radiotherapy not given for stem-cell transplant (HSCT).
Main reasons for not taking part
- Uncontrolled infection
- Pregnancy or breastfeeding
- Past allergy or intolerance to fluorothymidine
- Cannot have 18F FLT imaging without sedation
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 4 and 80 years old?
Source: NCT03633955, who can take part
Where in United States
- Emory UniversityAtlanta, United StatesNot yet recruiting
- University of Oklahoma Health Sciences CenterOklahoma City, United StatesTaking people
- Children's National Health SystemWashington D.C., United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Oklahoma
- Trial code
- NCT03633955
- Record updated
- 23 April 2026
- Original description
This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.Read full original descriptionShow less
Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging
This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.
Inclusion: Aged 4 to 80 years; Evidence of high-risk hematopoietic malignancy with relapsed/refractory disease: acute lymphocytic leukemia, Acute myeloid leukemia, Ambiguous lineage leukemia, myeloma; Karnofsky/Lansky score of ≥ 50; Agree to use contraceptive measures during study protocol participation (when age appropriate); Patient or parent/guardian capable of providing informed consent; Ability to undergo 18F FLT imaging without sedation; Bilirubin < 2.5 mg/dL, AST/ALT <5x upper limit of normal, Serum creatinine < 1.0 or 2x the upper limit of normal (whichever is higher); Pulse oximetry of > 90% on room air; Ability to undergo 18F FLT imaging without sedation; Anticipated immunotherapy (Arm A to include patients who received immune therapy with co-enrollment on a separate protocol or other immunotherapy) and Arm B, those who received other non-immune therapies to treat their cancers (excludes HSCT but includes chemotherapy or non-HSCT radiotherapy).
Exclusion: History of prior fluorothymidine allergy or intolerance; Patients with uncontrolled infections; Pregnancy or lactating.